Primary central nervous system post-transplant lymphoproliferative disorders (PCNS-PTLD) are rare complications of transplantation. Due to PCNS-PTLD’s scarcity, optimal treatments, risk factors, and outcomes are poorly characterized. By retrospective analysis of 20 patients treated at the University of Wisconsin between the years 2000–2022, we aimed to describe patient/disease characteristics, therapies received, and survival outcomes of PCNS-PTLD. Three separate clinical and pathological databases were reviewed to identify cases, with all patients having at least 2 years of long-term follow-up. Kaplan Meier survival curves were generated for cohorts treated from 2000–2010 (Cohort 1) and 2011–2022 (Cohort 2), with univariate and multivariable analysis performed for baseline variables associated with progression-free (PFS) and overall survival (OS). The median PFS was 59.2 months (95% confidence interval CI, 36.0–78.9 months) and the median OS was 71.2 months (95% CI, 47.6–91.6 months). Univariate analysis of patient sex, age, time to PTLD diagnosis, transplant type, transplant indication, time to treatment, therapy type, and baseline lactate dehydrogenase (LDH) showed that only lower LDH was associated with improved PFS (p=0.008) and OS (p=0.008). Over 2 decades, treatment practices had dramatically shifted from the frequent use of high-dose/intrathecal methotrexate and whole brain radiation in 75% of patients in Cohort 1, to use of first-line rituximab in 83% of patients in Cohort 2. Despite these key changes, there was no significant difference in OS or PFS between decades. Our findings support the use of less toxic therapies such as rituximab for PCNS-PTLD and encourage further investigation to optimize therapeutic approaches.
Uyemura et al. (Wed,) studied this question.